Regeneron Pharmaceuticals (STU:RGO) FFO


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
87 GF Score
Price €554.60
GF Value €788.02
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

STU:RGO
87GF Score
Regeneron Pharmaceuticals Inc STU:RGO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €554.60 is trading 29.6% below its estimated GF Value™ of €788.02. GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:RGO:

  • FFO:
  • GF Value™: €788.02 vs. price of €554.60 (29.6% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for STU:RGO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€554.60
Price
€788.02
GF Value